Drug Trial Radar · NCT06112743
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
Jan 24, 2024
Primary completion
Jul 16, 2026
Study completion Jun 10, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].
Conditions
- Cardiomyopathy, Hypertrophic
Interventions
MavacamtenDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48Time frame: At week 48
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0087
West Hollywood, California
Local Institution - 0003
Atlanta, Georgia
Local Institution - 0093
Boston, Massachusetts
Local Institution - 0090
Cleveland, Ohio
Local Institution - 0086
Pittsburgh, Pennsylvania
Local Institution - 0017
Houston, Texas
Local Institution - 0035
Murray, Utah
Local Institution - 0080
Buenos Aires, Argentina
Local Institution - 0076
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0075
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0079
Pilar, Buenos Aires, Argentina
Local Institution - 0077
Córdoba, Córdoba Province, Argentina
Local Institution - 0074
Rosario, Santa Fe Province, Argentina
Local Institution - 0015
Camperdown, New South Wales, Australia
Local Institution - 0085
Chermside, Queensland, Australia
Local Institution - 0005
Melbourne, Victoria, Australia
Local Institution - 0001
Montreal, Quebec, Canada
Local Institution - 0068
Québec, Quebec, Canada
Local Institution - 0061
Geneva, Switzerland
Local Institution - 0024
Zürich (de), Switzerland
Local Institution - 0058
Lucerne, Luzern (de), Switzerland
Local Institution - 0029
Lugano, Ticino (it), Switzerland
Local Institution - 0025
Leeds, Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.